Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential

Press/Media

Period	17 Nov 2022

Media coverage

Title	Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential
Media name/outlet	WIS-TV
Country/Territory	United States
Date	17/11/22
URL	https://www.wistv.com/prnewswire/2022/11/17/immunic-reports-new-data-phase-2-emphasis-trial-vidofludimus-calcium-relapsing-remitting-multiple-sclerosis-supporting-drugs-neuroprotective-potential/
Persons	Fred Lublin